IBO — Universal Ibogaine Share Price
Last trade - 00:00- CA$3.09m
- CA$5.39m
- CA$1.03m
- 11
- 46
- 27
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2 | ||
| Price to Tang. Book | 2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.39% | ||
| Return on Equity | -53.98% | ||
| Operating Margin | -34.57% | ||
Financial Summary
| Year End 31st Jul | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | 1.07 | 1.03 | n/a | n/a | -3.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Universal Ibogaine Inc. is a Canada-based life sciences company. The Company is focused on developing a network of addiction treatment clinics and undertake a planned clinical trial for research into the use of ibogaine for addiction treatment. Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree and other plants. Ibogaine is a neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state. Ibogaine has demonstrated effectiveness in treating opioid use disorder and it appears to eliminate the painful symptoms of opioid withdrawal and provides a several month window free of drug cravings. Ibogaine targets multiple receptor sites in the brain when it manages dopamine and serotonin circuits and stimulates new brain cell growth.
Directors
- Last Annual
- July 31st, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- March 10th, 2017
- Public Since
- June 21st, 2017
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 233,512,849
- Address
- (c/o Suite 600 - 815 8th Avenue SW, CALGARY, T2P 3P2
- Web
- https://universalibogaine.com/
- Phone
- +1 4038701841
- Auditors
- MNP LLP
Upcoming Events for IBO
Similar to IBO
ARCpoint
TSX Venture Exchange
Cannara Biotech
TSX Venture Exchange
Element Lifestyle Retirement
TSX Venture Exchange
Hempshire
TSX Venture Exchange
Jack Nathan Medical
TSX Venture Exchange
FAQ
As of Today at 11:57 UTC, shares in Universal Ibogaine are trading at CA$0.02. This share price information is delayed by 15 minutes.
Shares in Universal Ibogaine last closed at CA$0.02 and the price had moved by over the past 365 days. In terms of relative price strength the Universal Ibogaine share price has underperformed the Toronto Stock Exchange 300 Composite Index by -9.91% over the past year.
There is no consensus recommendation for this security.
Universal Ibogaine does not currently pay a dividend.
Universal Ibogaine does not currently pay a dividend.
Universal Ibogaine does not currently pay a dividend.
To buy shares in Universal Ibogaine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.02, shares in Universal Ibogaine had a market capitalisation of CA$3.50m.
Here are the trading details for Universal Ibogaine:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: IBO
Based on an overall assessment of its quality, value and momentum Universal Ibogaine is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Universal Ibogaine. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +192.5%.
As of the last closing price of CA$0.02, shares in Universal Ibogaine were trading +5.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Universal Ibogaine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Universal Ibogaine's directors